Stock listing
Lang & Schwarz:A426PN Cue Biopharma, Inc. Aktie
German listing (Lang & Schwarz) of Cue Biopharma, Inc. · home listing NASDAQ:CUE
Follow Cue Biopharma, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:CUE
$4.15 USD -0.35 (-7.8%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:CUE
- Day range
- $4.05 – $4.90 USDNov 20, 2026
- Volume
- 1.26M sharesNov 20, 2026
- Market cap
- $34.69M USDAt the close on Nov 20, 2026 · price × 8.36M shares outstanding
- 52-week range
- $2.83 – $45.50 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $7.66M USDMedian day 176,136 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:CUE · Home | $4.15 USD | -0.35 (-7.8%) | 1,263,468 | $4.52 | $4.90 | $4.05 | $4.50 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CUE · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $4.15 | -0.35 | -7.8% | $4.52 | $4.90 | $4.05 | 1,263,468 | |
| $4.50 | -0.26 | -5.5% | $4.48 | $5.16 | $3.851 | 2,088,520 | |
| $4.76 | +1.93 | +68.2% | $3.41 | $4.77 | $3.27 | 13,229,240 | |
| $2.83 | -11.27 | -79.9% | $13.02 | $13.52 | $2.83 | 4,229,479 | |
| $14.10 | -2.02 | -12.5% | $15.81 | $15.81 | $13.56 | 211,343 | |
| $16.12 | -1.38 | -7.9% | $17.69 | $17.69 | $14.30 | 274,955 | |
| $17.50 | -1.16 | -6.2% | $18.23 | $18.92 | $17.21 | 147,421 | |
| $18.66 | -0.10 | -0.5% | $19.24 | $19.99 | $18.51 | 122,973 | |
| $18.76 | -1.38 | -6.9% | $19.73 | $20.35 | $18.76 | 132,863 | |
| $20.14 | +1.41 | +7.5% | $18.90 | $21.20 | $17.95 | 187,454 | |
| $18.73 | +0.72 | +4.0% | $18.36 | $19.00 | $17.85 | 205,562 | |
| $18.01 | -1.83 | -9.2% | $19.35 | $19.74 | $16.87 | 141,747 | |
| $19.84 | -1.02 | -4.9% | $20.69 | $20.99 | $18.30 | 169,027 | |
| $20.86 | +1.44 | +7.4% | $19.66 | $21.00 | $19.01 | 181,890 | |
| $19.42 | -1.45 | -6.9% | $20.74 | $21.40 | $19.12 | 140,953 | |
| $20.87 | -0.58 | -2.7% | $20.66 | $21.17 | $19.85 | 60,773 | |
| $21.45 | +0.29 | +1.4% | $20.97 | $22.49 | $20.74 | 94,697 | |
| $21.16 | +2.84 | +15.5% | $18.46 | $21.79 | $18.44 | 157,542 | |
| $18.32 | -0.13 | -0.7% | $18.58 | $18.82 | $17.74 | 115,062 | |
| $18.45 | -0.21 | -1.1% | $18.48 | $18.85 | $17.89 | 181,714 | |
| $18.66 | -0.23 | -1.2% | $18.88 | $19.35 | $18.04 | 79,367 | |
| $18.89 | -0.06 | -0.3% | $18.57 | $19.48 | $18.29 | 54,610 | |
| $18.95 | +1.91 | +11.2% | $17.28 | $19.54 | $17.28 | 112,329 | |
| $17.04 | +0.96 | +6.0% | $15.98 | $17.93 | $15.93 | 169,203 | |
| $16.08 | -0.63 | -3.8% | $17.05 | $17.63 | $16.06 | 133,157 | |
| $16.71 | -1.96 | -10.5% | $18.57 | $18.87 | $16.54 | 106,567 | |
| $18.67 | +0.07 | +0.4% | $18.53 | $18.98 | $17.25 | 229,460 | |
| $18.60 | -0.97 | -5.0% | $20.01 | $20.79 | $18.09 | 245,074 | |
| $19.57 | -5.04 | -20.5% | $24.40 | $25.42 | $19.50 | 301,826 | |
| $24.61 | -3.05 | -11.0% | $27.44 | $29.00 | $24.48 | 179,427 | |
| $27.66 | +5.33 | +23.9% | $22.21 | $29.00 | $22.10 | 394,674 | |
| $22.33 | -0.18 | -0.8% | $22.38 | $22.74 | $21.60 | 109,897 | |
| $22.51 | -0.63 | -2.7% | $22.92 | $23.10 | $22.27 | 133,169 | |
| $23.14 | -1.22 | -5.0% | $24.22 | $24.89 | $22.92 | 174,848 | |
| $24.36 | -1.21 | -4.7% | $25.60 | $25.94 | $22.21 | 272,651 | |
| $25.57 | +0.32 | +1.3% | $25.60 | $25.92 | $24.67 | 157,036 | |
| $25.25 | -0.62 | -2.4% | $26.00 | $26.03 | $24.60 | 183,432 | |
| $25.87 | +0.36 | +1.4% | $25.89 | $27.43 | $24.88 | 228,119 | |
| $25.51 | -1.94 | -7.1% | $28.15 | $28.15 | $24.13 | 283,903 | |
| $27.45 | -3.96 | -12.6% | $30.86 | $32.07 | $27.01 | 237,825 | |
| $31.41 | -1.44 | -4.4% | $33.12 | $33.40 | $30.75 | 232,443 | |
| $32.85 | +1.14 | +3.6% | $31.15 | $33.64 | $30.44 | 330,395 | |
| $31.71 | +0.81 | +2.6% | $29.91 | $35.23 | $29.86 | 696,484 | |
| $30.90 | +2.63 | +9.3% | $28.61 | $32.39 | $25.49 | 1,205,815 | |
| $28.27 | -8.78 | -23.7% | $38.50 | $41.50 | $23.80 | 3,540,709 | |
| $37.05 | -0.79 | -2.1% | $39.35 | $41.00 | $35.54 | 381,952 | |
| $37.84 | +3.67 | +10.7% | $34.75 | $38.07 | $34.20 | 195,083 | |
| $34.17 | +2.53 | +8.0% | $31.27 | $36.47 | $30.33 | 277,389 | |
| $31.64 | +1.09 | +3.6% | $30.65 | $32.00 | $29.26 | 127,172 | |
| $30.55 | +1.81 | +6.3% | $28.24 | $31.10 | $28.24 | 136,595 | |
| $28.74 | +0.74 | +2.6% | $28.38 | $28.89 | $27.50 | 122,768 | |
| $28.00 | -2.50 | -8.2% | $30.20 | $30.91 | $27.50 | 143,189 | |
| $30.50 | +0.50 | +1.7% | $30.00 | $32.13 | $30.00 | 174,151 | |
| $30.00 | +2.56 | +9.3% | $27.39 | $30.24 | $25.62 | 260,041 | |
| $27.44 | -0.23 | -0.8% | $27.55 | $27.95 | $27.03 | 50,416 | |
| $27.67 | +0.71 | +2.6% | $26.60 | $28.09 | $26.60 | 65,684 | |
| $26.96 | -1.48 | -5.2% | $28.32 | $28.93 | $25.04 | 127,873 | |
| $28.44 | +2.92 | +11.4% | $25.29 | $29.28 | $25.01 | 177,424 | |
| $25.52 | -2.36 | -8.5% | $27.48 | $28.97 | $25.08 | 101,119 | |
| $27.88 | -0.28 | -1.0% | $28.64 | $29.75 | $26.85 | 102,262 | |
| $28.16 | -0.69 | -2.4% | $28.85 | $29.20 | $26.38 | 225,518 | |
| $28.85 | +2.09 | +7.8% | $26.63 | $29.33 | $26.26 | 205,087 | |
| $26.76 | +3.58 | +15.4% | $23.69 | $28.29 | $23.41 | 170,471 | |
| $23.18 | -0.80 | -3.3% | $23.97 | $24.19 | $22.56 | 136,572 | |
| $23.98 | -0.63 | -2.6% | $25.55 | $26.00 | $23.24 | 177,749 | |
| $24.61 | -1.67 | -6.4% | $26.44 | $28.11 | $24.40 | 158,053 |
Splits
1 split · NASDAQ:CUE · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-30 | Consolidation |
- Ticker
- Lang & Schwarz:A426PN
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Lang & Schwarz
- Currency
- EUR
What changed lately
Latest news release · Nov 16, 2026
Cue Biopharma Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Latest deck · September 2026
Technical Presentation (September 2026)
Technical · 23 slides
Latest news
Cue Biopharma Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Nov 16, 2026
Closed $2.83 (-79.9%) on Nov 17, 2026
Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria
Sep 20, 2026
Closed $28.27 (-23.7%) on Sep 21, 2026
Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission
Aug 3, 2026
Closed $26.87 (+0.1%) on Aug 3, 2026
Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development
Jul 13, 2026
Closed $30.92 (-15.9%) on Jul 13, 2026
Cue Biopharma Announces $50.0 Million Private Placement
Jul 9, 2026
Closed $36.78 (+0.7%) on Jul 10, 2026
Cue Biopharma Announces Board Transition and Addition of New Directors with Continued Company Evolution
Jun 2, 2026
Closed $26.91 (-6.0%) on Jun 3, 2026
Cue Biopharma to Present at the 2026 Jefferies Global Healthcare Conference
May 21, 2026
Closed $21.47 (+6.8%) on May 22, 2026
Cue Biopharma Reports First Quarter 2026 Financial Results and Recent Strategic Developments
May 14, 2026
Closed $23.01 (-9.2%) on May 15, 2026
Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 7, 2026
Closed $35.00 (-2.0%) on May 8, 2026
Cue Biopharma Announces $30 Million Private Placement
Apr 30, 2026
Closed $30.42 (+106.4%) on May 1, 2026
Cue Biopharma, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 22 in the last 12 months · 112 in all · newest Nov 16, 2026 · oldest 2019
- Calls
- 8 calls with a replay · 8 with a transcript · latest May 15, 2025
- Decks
- 33 decks · latest September 2026
Where Cue Biopharma, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:CUE · Home listing | NASDAQ | United States | USD |
| BOATS:CUE | BOATS | United States | USD |
| gettex:1UC0 | gettex | Germany | EUR |
| LS Exchange:A426PN | LS Exchange | Germany | EUR |
| Lang & Schwarz:A426PN · This page | Lang & Schwarz | Germany | EUR |
| Tradegate:1UC0 | Tradegate | Germany | EUR |
| Frankfurt:1UC0 | Frankfurt | Germany | EUR |
| Dusseldorf:1UC0 | Dusseldorf | Germany | EUR |
| Munich:1UC0 | Munich | Germany | EUR |
| Stuttgart:1UC0 | Stuttgart | Germany | EUR |
Valuation
EV/sales −0.7× against a median of 2.3×: 2nd lowest of 6 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$23.25M USD
- P/E
- Loss
- EV/sales
- −0.7×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.9×
- Gross margin
- Not reported
- Operating margin
- −387.7%
- Net margin
- −580.0%
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 2.35
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Cue Biopharma, Inc. · NASDAQ:CUE | US$34.69M | −US$23.25M | n/a | −0.7× | n/a | 0.9× | −580.0% | 0.0× | 2.35 |
| TaiRx, Inc. · TPEX:6580 | US$37.08M | US$28.62M | n/a | 33.8× | n/a | 3.3× | −793.3% | 0.0× | n/a |
| Pliant Therapeutics, Inc. · NASDAQ:PLRX | US$36.89M | −US$104.2M | n/a | n/a | n/a | 0.3× | n/a | 0.0× | 1.06 |
| Arovella Therapeutics Limited · ASX:ALA | US$36.04M | US$26.53M | n/a | n/a | n/a | 3.8× | n/a | 0.0× | n/a |
| Grace Therapeutics, Inc. · NASDAQ:GRCE | US$35.97M | US$14.66M | n/a | n/a | n/a | 0.7× | n/a | 0.0× | 0.77 |
| Cantargia AB · OMXSTO:CANTA | US$35.63M | US$13.87M | 2.2× | 0.5× | 0.9× | 1.4× | 52.8% | 0.0× | n/a |
| B&K Corporation Limited Class H · HKEX:2396 | US$33.15M | −US$47.28M | n/a | −603× | n/a | 0.4× | n/a | 0.0× | n/a |
| Veru Inc. · NASDAQ:VERU | US$33.08M | US$9.20M | n/a | n/a | n/a | 1.2× | n/a | 0.0× | 1.92 |
| Actinium Pharmaceuticals, Inc. (Delaware) · AMEX:ATNM | US$33.01M | US$5.49M | 3.1× | n/a | 0.6× | 1.3× | n/a | 0.1× | 0.71 |
| Neurizon Therapeutics Limited · ASX:NUZ | US$32.80M | US$26.57M | n/a | 2.3× | n/a | 3.9× | −61.0% | 0.3× | n/a |
| Transcenta Holding Limited · HKEX:6628 | US$32.41M | US$52.57M | n/a | 12.4× | n/a | 0.4× | −569.5% | 0.3× | n/a |
| Median of the others | US$34.39M | US$14.26M | 2.6× | 2.3× | 0.7× | 1.3× | −315.2% | 0.0× | 0.92 |
Forecasts
3 strong buy · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 88.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -25.01 · 3 analysts
- Revenue, year to Dec 2026
- 15.62M · 3 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Shao-Lee Lin | President, Chief Executive Officer and Board Director |
| James M. Ahlers | Chief Financial Officer |
| Sumita Ray | Chief Legal & Compliance Officer & Corporate Secretary |
| Agnes Lee | Chief Investor Relations & Communications Officer |
| Dominic Borie | Chief Medical Officer & Head of Research & Development |
| Ron Oyston | Chief Administrative Officer |
Board
| Director | Role |
|---|---|
| Pasha Sarraf | Chairman of the Board |
| Daniel Camardo | Board Member |
| Pamela D. Garzone | Board Member |
| Shao-Lee Lin | President, Chief Executive Officer and Board Director |
| Viola Meehan | Board Member |
Events
Calls
| Call | When | Status |
|---|---|---|
| Cue Biopharma (NASDAQ:CUE) Q1 2025 Earnings Call | Thu, May 15, 2025 · 11:00 AM ET | Replay |
| Cue Biopharma (NASDAQ:CUE) Q2 2024 Earnings Call | Mon, Aug 19, 2024 · 4:30 PM ET | Replay |
| Cue Biopharma (NASDAQ:CUE) Q4 2023 Earnings Call | Mon, Apr 08, 2024 · 4:30 PM ET | Replay |
| Cue Biopharma (NASDAQ:CUE) Q3 2023 Earnings Call | Thu, Nov 09, 2023 · 4:05 AM ET | Replay |
| Cue Biopharma (NASDAQ:CUE) Q2 2023 Earnings Call | Wed, Aug 09, 2023 · 4:30 PM ET | Replay |
| Cue Biopharma (NASDAQ:CUE) Q4 2022 Earnings Call | Tue, Mar 21, 2023 · 4:30 PM ET | Replay |
| Cue Biopharma (NASDAQ:CUE) Q3 2022 Earnings Call | Mon, Nov 14, 2022 · 4:30 PM ET | Replay |
| Cue Biopharma (NASDAQ:CUE) Q2 2022 Earnings Call | Tue, Aug 23, 2022 · 4:30 PM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 16, 2026 · After close | −79.9% |
| Q2 2026 | Aug 14, 2026 · After close | −19.2% |
| Q1 2026 | May 14, 2026 · After close | −9.2% |
| Q4 2025 | Mar 24, 2026 | −0.8% |
| Q3 2025 | Nov 12, 2025 · After close | −7.2% |
| Q2 2025 | Aug 12, 2025 · After close | +2.6% |
| Q1 2025 | May 12, 2025 · After close | +2.3% |
| Q4 2024 | Mar 26, 2025 · After close | +0.6% |
| Q3 2024 | Nov 14, 2024 · After close | −17.0% |
| Q2 2024 | Aug 14, 2024 · After close | −4.2% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 9, 2024 · After close | −9.1% |
| Q4 2023 | Mar 28, 2024 · After close | +0.5% |
| Q3 2023 | Nov 3, 2023 · After close | +4.1% |
| Q2 2023 | Aug 8, 2023 · After close | +1.1% |
| Q1 2023 | May 9, 2023 · After close | −2.5% |
| Q4 2022 | Mar 21, 2023 · After close | −2.1% |
| Q3 2022 | Nov 14, 2022 · After close | +16.3% |
| Q2 2022 | Aug 4, 2022 · After close | 0.0% |
| Q1 2022 | May 10, 2022 · After close | −15.0% |
| Q4 2021 | Mar 16, 2022 · After close | +19.7% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (September 2026) | Technical | 23 slides | September 2026 |
| Investor Presentation (July 2026) | Investor deck | 22 slides | July 2026 |
| Investor Presentation (June 2026) | Investor deck | 22 slides | Jun 3, 2026 |
| Investor Presentation (June 2026) | Investor deck | 11 slides | Jun 1, 2026 |
| Investor Presentation (June 2026) | Investor deck | 7 slides | June 2026 |
| Technical Presentation (April 2026) | Technical | 33 slides | Apr 7, 2026 |
| Investor Presentation (February 2026) | Investor deck | 23 slides | February 2026 |
| Investor Presentation (November 2025) | Investor deck | 26 slides | November 2025 |
| Corporate Update (April 2025) | Corporate update | 18 slides | Apr 15, 2025 |
| ASCO 2024 Oral Presentation | Conference | 17 slides | May 23, 2024 |
All 33 decks
Financings
| Raise | Date |
|---|---|
| Private placement of common stock and pre-funded warrants Announced: about US$50M · US$33.21 a share Buyers: Cormorant Asset Management; Columbia Threadneedle Investments Use of proceeds: Further fund clinical development and general corporate purposes | Jul 10, 2026 |
| Private placement of pre-funded warrants and accompanying common stock warrants Announced: about US$30M · US$11 a share · Warrants at US$11 · Newbridge Securities Corporation Dealers: Newbridge Securities Corporation (lead) Use of proceeds: Advance the clinical pipeline, including acquiring and developing Ascendant-221, working capital and general corporate purposes | Apr 30, 2026 |
| Public offering of shares of common stock (or pre-funded warrants) and accompanying common stock warrants Announced: about US$10M · US$0.28 a share · Warrants at US$0.3 for 60 months · H.C. Wainwright & Co. +1 Dealers: H.C. Wainwright & Co. (lead), Newbridge Securities Corporation | Dec 19, 2025 |
| Public offering of common stock and accompanying common stock warrants, pre-funded warrants Closed: US$20M raised · US$0.79 a share · Warrants at US$0.79 for 60 months · Oppenheimer & Co. Inc. +1 Dealers: Oppenheimer & Co. Inc. (lead), Newbridge Securities Corporation | Aug 12, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$7.50 a share on Dec 14, 2017.
- Price
- US$7.50 a share
- Listing
- CUE on the Nasdaq Capital Market
- Underwriters
- MDB Capital Group, LLC, Feltl and Company · In the order on the cover
Steps
| Step | When |
|---|---|
| Filed publicly | Sep 21, 2017 |
| Amended 5 times | Newest Dec 13, 2017 |
| Shares registered with an exchange | Dec 13, 2017 |
| Declared effective by the SEC | Dec 14, 2017 |
| Final prospectus, with the price | Dec 21, 2017 |
Filings
| Filing | Filed |
|---|---|
| 424B1 · Prospectus | Dec 21, 2017 |
| S-1MEF · Registration of more shares for the same offering | Dec 21, 2017 |
| CERT · Exchange's certificate of listing | Dec 18, 2017 |
| EFFECT · Notice that a registration is effective | Dec 14, 2017 |
| 8-A12B · Registration of shares for listing on an exchange | Dec 13, 2017 |
| CORRESP · Letter to the SEC | Dec 13, 2017 |
| S-1/A · Registration statement, amended | Dec 13, 2017 |
| CORRESP · Letter to the SEC | Dec 11, 2017 |
| S-1/A · Registration statement, amended | Dec 11, 2017 |
| UPLOAD · Letter from the SEC | Dec 6, 2017 |
All 21 filings
| Filing | Filed |
|---|---|
| S-1/A · Registration statement, amended | Dec 5, 2017 |
| FWP · Free writing prospectus | Dec 5, 2017 |
| CORRESP · Letter to the SEC | Dec 4, 2017 |
| UPLOAD · Letter from the SEC | Nov 30, 2017 |
| CORRESP · Letter to the SEC | Nov 17, 2017 |
| S-1/A · Registration statement, amended | Nov 17, 2017 |
| UPLOAD · Letter from the SEC | Nov 14, 2017 |
| S-1/A · Registration statement, amended | Nov 2, 2017 |
| CORRESP · Letter to the SEC | Nov 1, 2017 |
| UPLOAD · Letter from the SEC | Oct 23, 2017 |
| S-1 · Registration statement | Sep 21, 2017 |
Open IPO · From the cover of the final prospectus (424B1) filed Dec 21, 2017
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 27.5M | 9.29M | 5.49M | 1.25M | 14.9M | 3.15M | 3.46M | 1.14M | 0 | 0 |
| Cost of revenue | 3.48M | 2.35M | 38.1M | 1.81M | -1.78M | 33.5M | 27.5M | 28.5M | 419.6K | 202.1K |
| Gross profit | 27.5M | 9.29M | -32.6M | 1.25M | 14.9M | -30.4M | 3.46M | -27.4M | -419.6K | -202.1K |
| Research and development | 37.7M | 36.3M | 40.8M | 38.6M | 41.3M | 33.5M | 27.5M | 28.5M | 18.9M | 5.69M |
| Selling, general and administrative | 16.2M | 14.6M | 16.7M | 16.2M | 17.3M | 14.7M | 12.7M | 11.3M | 4.33M | 1.97M |
| Operating income | -26.6M | -41.5M | -52.1M | -53.2M | -43.7M | -45.0M | -36.8M | -38.7M | -23.2M | -7.66M |
| Depreciation and amortization | 958.0K | 397.0K | 556.0K | 922.0K | 1.26M | 1.06M | 810.8K | 760.0K | 419.6K | 202.1K |
| EBITDA | -25.6M | -41.1M | -51.6M | -52.3M | -42.5M | -44.0M | -36.0M | -37.9M | -22.8M | -7.46M |
| Interest expense | 100.0K | 100.0K | 100.0K | 109.0K | 1.73M | 463.9K | 5.65M | 0 | 0 | 0 |
| Income before tax | -26.1M | -40.7M | -50.7M | -53.0M | -43.7M | -44.6M | -36.3M | -38.2M | -23.2M | -7.66M |
| Income tax | 500.0K | 0 | 3.27M | 0 | 495.0K | 206.3K | 412.5K | 825.0K | 0 | 0 |
| Net income | -26.6M | -40.7M | -50.7M | -53.0M | -44.2M | -44.8M | -36.7M | -39.0M | -23.2M | -7.66M |
| Earnings per share, basic | -0.28 | -0.72 | -1.11 | -1.49 | -1.41 | -1.56 | -1.66 | -1.94 | -2.16 | -11.13 |
| Earnings per share, diluted | -0.28 | -0.72 | -1.11 | -1.49 | -1.41 | -1.56 | -1.66 | -1.94 | -2.16 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 27.1M | 22.5M | 48.5M | 51.6M | 64.4M | 74.9M | 44.3M | 20.8M | 63.5M | 14.9M |
| Short-term investments | 0 | 0 | 24.7M | 0 | 10.0M | 15.1M | 18.4M | 0 | 50.0K | |
| Receivables | 5.55M | 945.0K | 1.70M | 57.0K | 3.14M | 1.42M | 754.9K | 852.4K | ||
| Inventory | 1 | 1 | 1 | 15.1M | 225.5K | |||||
| Current assets | 37.0M | 25.1M | 51.5M | 77.2M | 68.5M | 87.5M | 61.0M | 40.6M | 65.1M | 15.1M |
| Property, plant and equipment | 241.0K | 471.0K | 795.0K | 1.50M | 2.11M | 2.11M | 1.85M | 2.78M | 1.69M | 1.02M |
| Total assets | 42.2M | 32.2M | 61.5M | 91.3M | 83.4M | 99.5M | 71.6M | 45.4M | 67.0M | 16.3M |
| Accounts payable | 3.95M | 2.82M | 3.50M | 2.73M | 2.59M | 2.07M | 882.7K | 2.04M | 1.66M | 523.8K |
| Current liabilities | 13.5M | 13.7M | 17.1M | 11.5M | 12.8M | 16.3M | 11.7M | 6.22M | 5.35M | 1.07M |
| Long-term debt | 0 | 4.20M | 8.04M | 0 | ||||||
| Total debt | 4.20M | 37.0K | 4.04M | 8.07M | 0 | 7.15M | 5.80M | 2.50M | ||
| Total liabilities | 15.8M | 14.7M | 24.4M | 25.6M | 17.9M | 20.6M | 17.0M | 11.4M | 5.35M | 1.10M |
| Shareholders' equity | 26.4M | 17.5M | 37.1M | 65.7M | 65.5M | 78.9M | 54.6M | 34.0M | 61.6M | 15.2M |
| Shares outstanding | 3.22M | 61.8M | 47.2M | 47.2M | 32.2M | 30.4M | 26.6M | 20.7M | 19.5M | 688.0K |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -21.7M | -36.3M | -40.0M | -41.8M | -38.8M | -32.5M | -30.8M | -26.4M | -12.1M | -5.97M |
| Capital spending | -177.0K | -66.0K | 0 | -171.0K | -913.0K | -595.3K | -46.4K | -1.85M | -1.03M | -516.0K |
| Free cash flow | -21.9M | -36.4M | -40.0M | -42.0M | -39.8M | -33.1M | -30.8M | -28.3M | -13.2M | -6.48M |
| Cash from investing | 75.0K | 32.0K | 25.0M | -24.6M | 9.11M | 4.46M | 3.45M | -20.4M | -1.20M | -516.0K |
| Cash from financing | 26.3M | 10.2M | 11.9M | 53.7M | 19.2M | 58.6M | 50.8M | 4.18M | 62.0M | 15.0M |
| Dividends paid | -199.9K | |||||||||
| Share buybacks | 0 | -200.0K | -750.1K | -271.1K | -91.0K | 4.18M | -4.16M | -1.41M | ||
| Change in cash | 4.68M | -26.1M | -3.10M | -12.8M | -10.5M | 30.6M | 23.4M | -42.6M | 48.7M | 8.52M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 16, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 16, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 10, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 14, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 13, 2026 | Other filings | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 144 · Notice of proposed sale | Oct 13, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 8, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Sep 21, 2026 | Current report | SEC |
| 4/A · Change in ownership, amended | Aug 28, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Aug 28, 2026 | Insider trade | SEC |
| SCHEDULE 13D · Big-stake notice | Aug 21, 2026 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Aug 21, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 18, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 17, 2026 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Aug 17, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 14, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 14, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Aug 13, 2026 | Other filings | SEC |
| S-3 · Registration statement | Aug 12, 2026 | Offer document | SEC |
| 8-K · Current report | Aug 3, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Aug 3, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 3, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jul 30, 2026 | Insider trade | SEC |
| D | Jul 22, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jul 15, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 10, 2026 | Insider trade | SEC |
| 8-K · Current report | Jul 10, 2026 | Material contract | SEC |
| EFFECT · Notice that a registration is effective | Jul 2, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jun 29, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jun 25, 2026 | Other filings | SEC |
| S-3 · Registration statement | Jun 18, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jun 18, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jun 15, 2026 | Other filings | SEC |
| 3 · Initial statement of ownership | Jun 11, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 11, 2026 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Jun 10, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 3, 2026 | Management or board change | SEC |
| S-8 · Registration statement for employee plans | Jun 3, 2026 | Offer document | SEC |
| S-3 · Registration statement | Jun 3, 2026 | Offer document | SEC |
| 4 · Change in ownership | Jun 2, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 2, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 2, 2026 | Management or board change | SEC |
| DEF 14A · Proxy statement | May 21, 2026 | Meeting notice | SEC |
| 8-K · Current report | May 14, 2026 | Current report | SEC |
| 10-Q · Quarterly report | May 14, 2026 | Quarterly report | SEC |
| D | May 14, 2026 | Other filings | SEC |
| PRE 14A · Preliminary proxy statement | May 12, 2026 | Meeting notice | SEC |
| 3 · Initial statement of ownership | May 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 7, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Apr 30, 2026 | Offer document | SEC |
| 8-K · Current report | Apr 30, 2026 | Material contract | SEC |
| 8-K · Current report | Apr 22, 2026 | Current report | SEC |
| 8-K · Current report | Apr 13, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Apr 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 10, 2026 | Insider trade | SEC |
| 8-K · Current report | Apr 7, 2026 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Apr 1, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Mar 27, 2026 | Other filings | SEC |
| DEFA14A · Additional proxy material | Mar 27, 2026 | Meeting notice | SEC |
| 8-K · Current report | Mar 27, 2026 | Management or board change | SEC |
| UPLOAD · Letter from the SEC | Mar 23, 2026 | Other filings | SEC |
| S-3 · Registration statement | Mar 17, 2026 | Offer document | SEC |
| ARS · Annual report to shareholders | Mar 16, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Mar 16, 2026 | Meeting notice | SEC |
| 8-K · Current report | Mar 16, 2026 | Results | SEC |
| 10-K · Annual report | Mar 16, 2026 | Annual report | SEC |
| PRE 14A · Preliminary proxy statement | Mar 6, 2026 | Meeting notice | SEC |
| 8-K · Current report | Feb 18, 2026 | Current report | SEC |
| 8-K · Current report | Feb 12, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 29, 2025 | Other filings | SEC |
| 8-K · Current report | Dec 19, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Dec 19, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Dec 18, 2025 | Offer document | SEC |
| 4 · Change in ownership | Dec 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 25, 2025 | Insider trade | SEC |
| 8-K · Current report | Nov 24, 2025 | Current report | SEC |
| 8-K · Current report | Nov 20, 2025 | Management or board change | SEC |
| 10-Q · Quarterly report | Nov 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2025 | Results | SEC |
| 8-K · Current report | Nov 6, 2025 | Material contract | SEC |
| 4 · Change in ownership | Oct 2, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 2, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 29, 2025 | Management or board change | SEC |
| S-8 · Registration statement for employee plans | Aug 12, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2025 | Results | SEC |
| 8-K · Current report | Jul 1, 2025 | Material contract | SEC |
| 8-K · Current report | Jun 10, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 6, 2025 | Insider trade | SEC |
| DEFA14A · Additional proxy material | May 27, 2025 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 16, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 12, 2025 | Results | SEC |
| ARS · Annual report to shareholders | Apr 25, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 25, 2025 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Apr 25, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 15, 2025 | Results | SEC |
| 424B5 · Prospectus | Apr 15, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Apr 14, 2025 | Offer document | SEC |
| 8-K · Current report | Apr 14, 2025 | Material contract | SEC |
| PRE 14A · Preliminary proxy statement | Apr 14, 2025 | Meeting notice | SEC |
| S-8 · Registration statement for employee plans | Mar 31, 2025 | Offer document | SEC |
| 8-K · Current report | Mar 31, 2025 | Results | SEC |
| 10-K · Annual report | Mar 31, 2025 | Annual report | SEC |
| 4 · Change in ownership | Mar 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 25, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 21, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Mar 12, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Mar 12, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 12, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2024 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Dec 16, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 11, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Dec 5, 2024 | Other filings | SEC |
| 4 · Change in ownership | Nov 29, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 29, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2024 | Results | SEC |
| 8-K · Current report | Oct 8, 2024 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 7, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Oct 4, 2024 | Material contract | SEC |
| 8-K · Current report | Sep 27, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Sep 27, 2024 | Offer document | SEC |
| 424B5 · Prospectus | Sep 26, 2024 | Offer document | SEC |
| DEF 14A · Proxy statement | Sep 10, 2024 | Meeting notice | SEC |
| 3 · Initial statement of ownership | Sep 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 5, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 3, 2024 | Management or board change | SEC |
| PRE 14A · Preliminary proxy statement | Aug 28, 2024 | Meeting notice | SEC |
| 8-K · Current report | Aug 16, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Aug 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Jul 25, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 7, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| DEFA14A · Additional proxy material | May 24, 2024 | Meeting notice | SEC |
| 8-K · Current report | May 9, 2024 | Results | SEC |
| 10-Q · Quarterly report | May 9, 2024 | Quarterly report | SEC |
| DEF 14A · Proxy statement | Apr 26, 2024 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Apr 26, 2024 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 26, 2024 | Annual report | SEC |
| S-8 · Registration statement for employee plans | Mar 28, 2024 | Offer document | SEC |
| 10-K · Annual report | Mar 28, 2024 | Annual report | SEC |
| SC 13G · Big-stake notice | Mar 11, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 22, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Feb 7, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Jan 31, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 4, 2024 | Insider trade | SEC |
This page holds 200 of 558 filings. Open Filings
Cap table
Built by 6ix from Cue Biopharma, Inc.’s releases · as of Nov 13, 2026
- Common shares
- 8,359,523
- Fully diluted
- 8,359,523
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 8,359,523 | Nov 13, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · US$0.79 · expire about Apr 2030 |
Share count over time
| Count | Shares |
|---|---|
| Nov 13, 2026 | 8,359,523 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Frederick W. Driscoll Other companies: Lite Strategy, Inc. (Chairperson, Non-Executive Director · Since at least Feb 22, 2018); Cellectar Biosciences, Inc. (Director · Since at least Apr 10, 2017); Invivyd, Inc. (Interim CFO · Oct 13, 2022 – Oct 13, 2022 · Past); ConforMIS Inc (INTERIM CFO & INTERIM TREAS · Oct 23, 2019 – Oct 23, 2019 · Past); ImmunityBio, Inc. (Director · Sep 18, 2017 – Aug 11, 2020 · Past); Flexion Therapeutics Inc (Chief Financial Officer · Feb 11, 2014 – Nov 19, 2021 · Past); Oncotelic Therapeutics Inc (Director · Jan 1, 2014 – Jun 1, 2016 · Past); Novavax, Inc. (VP, CFO & Treasurer · Aug 24, 2009 – Mar 2, 2013 · Past); Genelabs Technologies Inc (CEO/PRESIDENT · Nov 1, 2007 – Jan 7, 2009 · Past) | Director · Jun 26, 2018 – Jan 2, 2025 · Past |
| Anthony DiGiandomenico Other companies: Illumination Acquisition Corp I (Director · Since at least Feb 26, 2026); ClearSign Technologies Corporation (Director · Since at least May 22, 2025); eXoZymes Inc. (Board Member · Since at least Nov 8, 2024); MDB Capital Holdings, LLC (Co-Founder, Head of New Venture Discovery · Since at least Jul 25, 2023); ENDRA Life Sciences Inc. (Director · Since at least May 8, 2017); Provention Bio Inc (Director · Jul 3, 2018 – May 15, 2020 · Past); Charlie's Holdings, Inc. (Director · Aug 4, 2006 – Aug 27, 2012 · Past) | Director · Dec 18, 2017 – Jan 2, 2019 · Past |
| Aaron G.L. Fletcher Other companies: Actuate Therapeutics, Inc. (Chairman · Since at least Aug 12, 2024); Cognition Therapeutics, Inc. (Director · Since at least Oct 7, 2021); IN8bio, Inc. (Director · Aug 16, 2022 – Dec 12, 2022 · Past); TFF Pharmaceuticals Inc (Director · Oct 24, 2019 – Dec 29, 2022 · Past); SWK Holdings Corp (Director · Sep 3, 2019 – Dec 31, 2021 · Past) | Director · Oct 3, 2019 – Jan 3, 2023 · Past |
| Shao-Lee Lin Other companies: Acelyrin, Inc. (Chief Executive Officer, Director · May 4, 2023 – Apr 1, 2024 · Past); Third Harmonic Bio Inc. (Director · Sep 14, 2022 – Oct 26, 2022 · Past); Surrozen, Inc. (Director · Aug 11, 2021 – May 14, 2025 · Past); Principia Biopharma Inc (Director · Apr 16, 2019 – Sep 28, 2020 · Past); Horizon Pharma PLC (EVP, Head of R&D and CSO · Jan 4, 2018 – Feb 20, 2019 · Past) | President, Chief Executive Officer and Board Director · Since at least Apr 30, 2026 |
| Sumita Ray Other companies: Biomea Fusion, Inc. (Director · Since at least Jun 16, 2021); Vaxxinity, Inc. (Chief Legal, Comp & Admin Off · Oct 1, 2023 – Nov 1, 2023 · Past); Instil Bio, Inc. (Chief Legal and Admin Officer · May 3, 2022 – Jan 8, 2023 · Past); Calithera Biosciences, Inc. (See Remarks · Sep 29, 2017 – Jan 25, 2022 · Past); Pharmacyclics Inc (Chief Compliance Officer · Jun 24, 2013 – Oct 31, 2013 · Past) | Chief Legal & Compliance Officer & Corporate Secretary · Since at least Jun 1, 2026 |
| Jill Marie Broadfoot Other companies: Talphera, Inc. (Director · Since at least Nov 20, 2021); aTyr Pharma, Inc. (Chief Financial Officer · Since at least Jul 30, 2018); Otonomy Inc (Director · Aug 18, 2021 – Jun 21, 2022 · Past); Vical Incorporated (Sr Vice President, CFO, Sec · Jan 7, 2011 – Apr 1, 2013 · Past) | Director · Since at least Jun 4, 2025 |
| Peter A Kiener Other companies: LAVA Therapeutics NV (Director · Since at least Jan 1, 2025); Palvella Therapeutics, Inc. (Director · Sep 7, 2018 – Jun 21, 2023 · Past); Sucampo Pharmaceuticals Inc (Chief Science Officer · Mar 4, 2015 – Feb 13, 2018 · Past); Medimmune Inc (SVP, Research · Feb 8, 2006 – Feb 23, 2006 · Past) | Director · Since at least Dec 18, 2017 |
| Tamar D Howson Other companies: Immunic, Inc. (Director · Since at least Oct 11, 2019); Lite Strategy, Inc. (Director · Jul 1, 2019 – Sep 29, 2023 · Past); VivoSim Labs, Inc. (Director · Jul 26, 2018 – Jul 26, 2018 · Past) | Director · Sep 17, 2020 – Jan 3, 2023 · Past |
| Barry Simon Other companies: ImmunityBio, Inc. (Chief Corporate Affairs Officer · Since at least Jul 27, 2015); Viracta Therapeutics Inc (Director · Mar 3, 2021 – Jun 20, 2024 · Past) | Director · Dec 18, 2017 – Jan 4, 2021 · Past |
| Cameron Gray Other companies: Provention Bio Inc (Director · Jul 3, 2018 – Jul 19, 2018 · Past); Endeavor IP Inc (CEO, CFO, Secretary, Treasurer, Director · May 13, 2013 – May 13, 2013 · Past) | Director · Dec 18, 2017 – Jun 14, 2022 · Past |
All 39 people
| Person | Seat |
|---|---|
| Christopher Marlett Other companies: eXoZymes Inc. (Chairman of the Board · Since at least Nov 8, 2024); MDB Capital Holdings, LLC (Chief Executive Officer, Chairman of Board and Director · Since at least Jul 25, 2023) | Director · Dec 18, 2017 – Jan 2, 2020 · Past |
| Daniel Baker Other companies: Shattuck Labs, Inc. (Director · Since at least Aug 25, 2025); Artiva Biotherapeutics, Inc. (Director · Since at least Jan 28, 2025) | CHIEF DEVELOPMENT OFFICER · Since at least Nov 25, 2024 |
| James M. Ahlers Other companies: Intensity Therapeutics, Inc. (Executive Vice President · Since at least Jun 29, 2023); RenovoRx, Inc. (Chief Financial Officer · Jul 15, 2022 – Jul 15, 2022 · Past) | Chief Financial Officer · Since at least Jul 30, 2026 |
| Michael J Fox Other companies: Resonant Inc (Director · Feb 16, 2016 – Mar 28, 2022 · Past); Regional Health Properties, Inc. (Director · Oct 1, 2013 – Apr 24, 2018 · Past) | Director · Jun 5, 2024 – Jun 5, 2024 · Past |
| Daniel R Passeri Other companies: Curis, Inc. (Director · May 31, 2006 – Jan 19, 2016 · Past) | CHIEF EXECUTIVE OFFICER, Director · Dec 18, 2017 – Mar 21, 2025 · Past |
| Dominique Christian Borie Other companies: Kyverna Therapeutics, Inc. (See Remarks · Feb 7, 2024 – Feb 7, 2024 · Past) | Chief Medical Officer · Since at least Jul 13, 2026 |
| Frank Morich Other companies: Perspective Therapeutics, Inc. (Director · Since at least Feb 3, 2023) | Director · Since at least Jul 31, 2018 |
| Gary Schuman Other companies: MDB Capital Holdings, LLC (Head of Compliance · Since at least Nov 5, 2026) | Interim CFO · Dec 18, 2017 – Dec 18, 2017 · Past |
| Kenneth Pienta Other companies: Curis, Inc. (Director · Mar 7, 2013 – Feb 28, 2017 · Past) | Chief Medical Officer · Dec 18, 2017 – Mar 25, 2022 · Past |
| Agnes Lee | Chief Investor Relations & Communications Officer · Since at least Sep 20, 2026 |
| Anish Suri | PRESIDENT AND CSO · May 14, 2018 – Jun 5, 2024 · Past |
| Bethany Mancilla | SVP and Chief Business Officer · Aug 1, 2018 – Mar 6, 2019 · Past |
| Colin Sandercock | SVP, GENERAL COUNSEL · Since at least Dec 18, 2017 |
| Daniel Camardo | Board Member · Since at least May 30, 2026 |
| Dominic Borie | Chief Medical Officer & Head of Research & Development · Since at least Jul 13, 2026 |
| Kerri-Ann Millar | CHIEF FINANCIAL OFFICER · May 1, 2018 – Mar 21, 2025 · Past |
| Lucinda Warren | CHIEF BUSINESS OFFICER · Since at least Sep 3, 2024 |
| Matteo Levisetti | Chief Medical Officer · Jan 17, 2023 – Mar 21, 2025 · Past |
| Michael Vincent Meluzio | VP, Prin. Accounting Officer · Since at least Jun 1, 2026 |
| Pamela D. Garzone | Board Member · Since at least Apr 19, 2023 |
| Pasha Sarraf | Chairman of the Board · Since at least Mar 10, 2025 |
| Patricia Nasshorn | Chief Business Officer · Dec 15, 2021 – Feb 16, 2023 · Past |
| Patrick Verheyen | Director · Since at least Apr 11, 2023 |
| Rodolfo Chaparro | EVP, Head of Immunology · Dec 18, 2017 – Jul 23, 2018 · Past |
| Ronald D Seidel III | EVP, Head of R&D · Dec 18, 2017 – Jul 23, 2018 · Past |
| Ron Oyston | Chief Administrative Officer · Since at least Nov 4, 2026 |
| Steven L McKnight | Director · Dec 18, 2017 – Jan 6, 2020 · Past |
| Usman Azam | CHIEF EXECUTIVE OFFICER, Director · Since at least Sep 29, 2025 |
| Viola Meehan | Board Member · Since at least May 30, 2026 |
Log in to ask 6ix AI your own questions about Cue Biopharma, Inc.